Craft
  • Home
  •  / Angion Biomedica
Angion Biomedica

Angion Biomedica

Revenue

$28.3 M

FY, 2021

Total Funding

$19.7 M

Angion Biomedica Summary

Company summary

Overview
Angion Biomedica Corp is a biopharmaceutical company focused on acute kidney injury, acute lung injury, and CNS injury. It focuses on the discovery, development, and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The company develops treatments for delayed graft function, cardiac surgery-associated acute kidney injury, anti-fibrotic (chronic kidney disease, IPF) indications, etc.
Type
Private
Status
Active
Founded
1998
HQ
San Francisco, CA, US | view all locations
Website
https://angion.com/
Cybersecurity rating
Sectors

Key people

  • Allen R. Nissenson

    Allen R. Nissenson, Director

    • Victor F. Ganzi

      Victor F. Ganzi, Director

      • Gilbert S. Omenn

        Gilbert S. Omenn, Director

        • Karen Wilson

          Karen Wilson, Director

          Operating MetricsView all

          Patents (US)

          19

          Mar, 2021

          Patent Applications (US)

          28

          Mar, 2021

          Trademarks (US)

          1

          Mar, 2021

          LocationsView all

          2 locations detected

          • San Francisco, CA HQ

            United States

            1700 Montgomery St Suite 108, San Francisco

          • Uniondale, NY

            United States

            51 Charles Lindbergh Blvd

          Angion Biomedica Financials

          Summary financials

          Revenue (Q2, 2022)
          $653.0K
          Net income (Q2, 2022)
          ($9.1M)
          Cash (Q3, 2022)
          $55.1M
          EBIT (Q2, 2022)
          ($9.0M)

          Footer menu